Danaher Co. (NYSE:DHR) Shares Sold by Cibc World Markets Corp

Cibc World Markets Corp reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 41.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,353 shares of the conglomerate’s stock after selling 115,496 shares during the period. Cibc World Markets Corp’s holdings in Danaher were worth $37,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in DHR. Gilbert & Cook Inc. boosted its stake in shares of Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares during the period. Grimes & Company Inc. lifted its stake in Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after purchasing an additional 43 shares during the last quarter. Harbour Investments Inc. lifted its position in shares of Danaher by 3.0% during the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock worth $426,000 after buying an additional 45 shares during the last quarter. Dakota Community Bank & Trust NA boosted its holdings in shares of Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after buying an additional 45 shares in the last quarter. Finally, Howard Capital Management Group LLC increased its position in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 48 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of NYSE DHR opened at $211.09 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market cap of $150.87 billion, a PE ratio of 39.98, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. The company has a 50-day simple moving average of $220.07 and a 200-day simple moving average of $240.45. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Friday, March 28th. Danaher’s payout ratio is presently 24.24%.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DHR. Citigroup reduced their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Wells Fargo & Company reduced their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Jefferies Financial Group cut their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $277.76.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.